TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05408689

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T1 TENS
Description: The subjects in Group A will received TENS (Burst mode, 9 pulses per burst, pulse frequency =160Hz, burst frequency=2Hz, intensity was set to trigger visible muscular twitches). Two 2 x 3 cm electrodes was attached on T1 level with 2 cm from the spine. Previous study has shown that it was effective to improve the cognitive function in subjects with Alzheimer's disease.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Concha TENS
Description: The subjects in Group B will received TENS (25Hz, 0.5mA) on the concha of left outer ear. The electrical stimulation was generated by the portable neurostimulator (Nemos®, Cerbomed, Erlangen, Germany) and was delivered by a titanium electrodes positioning on top of a silicon earplug. Previous study has shown that it was effective to improve the Accelerate extinction memory formation and retention in healthy young adults.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The subjects in Group C will receive 30 min sham electrical stimulation on T1 by a placebo-TENS device. The Placebo-TENS was applied by an apparently identical TENS unit. The unit's power indicator light was illuminated, but the unit's electrical circuit had been manually disconnected inside. In order to shape the common mindset, all subjects (except those in the Control group) were informed that they might or might not feel an electrical current, as different stimulation parameters were being applied.
Study: NCT04964869

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: epinephrine solution injection
Description: epinephrine solution injection at least 1 ml to the post- sphincterotomy wound
Study: NCT06174168

Intervention type: OTHER
Intervention: Modified Frailty Index -11
Description: MFI-11: the parameter included in the score is history of congestive heart failure, presence of diabetes mellitus, history of chronic obstructive pulmonary disease or pneumonia, functional health status/dependence, history of hypertension, history of myocardial infarction, cardiac problems, cognitive impairment, history of transient ischemic attack or cerebrovascular accident, history of peripheral vascular disease is questioned. Patients will be monitored according to standard non-operating room anesthesia procedures.

Intervention type: OTHER
Intervention: Modified Frailty Index -11
Description: MFI-11: the parameter included in the score is history of congestive heart failure, presence of diabetes mellitus, history of chronic obstructive pulmonary disease or pneumonia, functional health status/dependence, history of hypertension, history of myocardial infarction, cardiac problems, cognitive impairment, history of transient ischemic attack or cerebrovascular accident, history of peripheral vascular disease is questioned. Patients will be monitored according to standard non-operating room anesthesia procedures.
Study: NCT06470880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adaptive Therapy
Description: A blood test that measures the amount of tumour DNA circulating in the patient's blood (known as ctDNA) will be conducted every two weeks to check if the cancer cells are still present, and if they are becoming active. The result of this test will allow doctors to monitor the activity of the tumour and judge when to pause and resume encorafenib and binimetinib treatment. This intermittent treatment is called 'adaptive therapy'.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Encorafenib and binimetinib delivered to UK standard of care.
Study: NCT05963178

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-operative counselling
Description: A preoperative speech therapy counseling will be carried out the day before the Total Thyroidectomy with the aim of informing patients about the possible conditions of the immediate post-operative period. Therefore, indications of vocal hygiene and hydration standards will be simultaneously administered, to be implemented from the first post-operative day.~Patients will undergo phoniatric follow-up in the immediate post-operative period, at 7 days, 1 month and 3 months post-operatively.~Patients who, at follow-up checks, should present the symptoms of functional post-thyroidectomy syndrome will undergo a cycle of post-operative speech therapy of 8 sessions.
Study: NCT05591781

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high frequency chest wall oscillation with vest system
Description: Patients were assigned to 2 groups with pre- and post- treatment protocol application. All patients were thoroughly evaluated before and after treatment protocol application.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lung flute (OPEP)
Description: . Thirty patients (Group B) received Lung flute (OPEP) in addition to their prescribed medication, 3 times per week twice a day for three successive weeks
Study: NCT06250387

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endobronchial ultrasound transbronchial cryobiopsy
Description: Endobronchial Ultrasound (EBUS) :~EBUS is usually performed under general anesthesia using a laryngeal masque. It has a linear ultrasonography with a 7.5 MHz frequency. The distal part of the endoscope contains a water filled balloon used as a liquid interface, camera, light source and a working channel. The needle is protected by a sheath to prevent working channel damage. The endoscope is connected to a processor that reflects both endobronchial and ultrasound images on a screen.~EBUS - TBNA : EBUS - Transbronchial needle aspiration EBUS - TBCB: EBUS - Transbronchial Cryo Biopsy
Study: NCT05384730

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group nutrition and exercise support
Description: Weekly group nutrition and exercise support delivered online through trained volunteers
Study: NCT05726357

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vital pulp therapy
Description: removal of the coronal pulp followed by placing a biocompatible material to preserve the vitality of the radicular pulp

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vital pulp therapy
Description: removal of the coronal pulp followed by placing a biocompatible material to preserve the vitality of the radicular pulp
Study: NCT04693143

Intervention type: OTHER
Group type: OTHER
Intervention: A randomized controlled open-label clinical trial.
Description: This was a single-center; open-label randomized controlled trial performed at a Pediatric Intensive Care Unit (PICU) in tertiary care hospital
Study: NCT06418178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midomafetamine
Description: One to five MDMA-assisted therapy sessions, each followed by three non-drug psychotherapy sessions (see behavioral intervention below)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Standardized psychotherapy performed by therapy team
Study: NCT04444245

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lipoaspiration harvest tSVF
Description: Use of disposable, sterile microcannula lipoharvest to acquire tSVF

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lipoaspiration harvest tSVF
Description: Use of disposable, sterile microcannula lipoharvest to acquire tSVF

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lipoaspiration harvest tSVF
Description: Use of disposable, sterile microcannula lipoharvest to acquire tSVF

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: Standard venipuncture, concentration of PRP in FDA approved device (Emcyte II)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: Standard venipuncture, concentration of PRP in FDA approved device (Emcyte II)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: Standard venipuncture, concentration of PRP in FDA approved device (Emcyte II)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovaginal Ultrasound
Description: Endovaginal Ultrasound guidance to intra-ovarian placement, bilaterally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovaginal Ultrasound
Description: Endovaginal Ultrasound guidance to intra-ovarian placement, bilaterally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovaginal Ultrasound
Description: Endovaginal Ultrasound guidance to intra-ovarian placement, bilaterally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovaginal Ultrasound
Description: Endovaginal Ultrasound guidance to intra-ovarian placement, bilaterally

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellular Isolation cSVF
Description: Digestion of tSVF with Liberase, isolation \& concentration of cSVF in Centricyte 1000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline (NS) .9% 10 mL Injection
Description: 10 cc Sterile Normal Saline for Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline (NS) .9% 10 mL Injection
Description: 10 cc Sterile Normal Saline for Injection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: emulsification tSVF
Description: Harvested tSVF emulsification with sterile, disposable Nanofat screen device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: emulsification tSVF
Description: Harvested tSVF emulsification with sterile, disposable Nanofat screen device
Study: NCT06001567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag
Description: Avatrombopag (platelet count \[PLT\] \<40×10\^9/L, 60mg P.O. QD; PLT of 40-75×10\^9/L, 40mg P.O. QD) will be administered to the patients and last 5-10 days. When the PLT reaches ≥100×10\^9/L, the treatment will be discontinued.
Study: NCT06114524

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: binaural music
Description: In the binaural music group, an MP3 player and in-ear stereo headphones were provided. Music therapy was applied for 15 min before the procedure.
Study: NCT05939778

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TH-SC01(Umbilical cord mesenchymal stem cells)
Description: 5+7 principle:~1. In medium and high dose groups, 5 subjects were included in each dose group in the first step, and the first 3 subjects had good safety The investigator evaluated safety and efficacy data and could enroll a fourth and fifth subject.~1. If the number of successful participants in these 5 subjects is less than 2, the study in this dose group will be ended due to drug ineffectiveness, and the researcher will evaluate the safety and enter the next dose group.~2. If the number of successful participants in these 5 cases is greater than or equal to 2, then proceed to the second step.~2. 7 subjects were included in the second step.
Study: NCT05196711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAX-40070
Description: In the SAD phase, the proposed doses will be increased gradually. Each cohort will consist of 8 subjects, with 6 subjects randomly assigned to MAX-40070.~During the MAD phase, the treatment will be administered once a day for 14 consecutive days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In the SAD phase, the proposed doses will be increased gradually. Each cohort will consist of 8 subjects, with 2 subjects randomly assigned to placebo~In the MAD phase, the treatment will be administered once a day for 14 consecutive days. Each cohort will consist of 10 subjects, with 2 subjects randomly assigned to placebo
Study: NCT05725759

Intervention type: BEHAVIORAL
Intervention: Rehabilitation
Description: Particapants currently receiving tofersen treatment will be referred to outpatient physical and/or occupational therapy.
Study: NCT05731921

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The exercise program with the 'Empathy Dress'
Description: The experimental group will be given an exercise program that includes a total of eight sessions (two months) of 'Empathy Dress' and some exercises (stairs going up and down, sitting up, putting on trousers, tying shoes, etc.), every week and 20 minutes per week, by the researchers.
Study: NCT05981066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoantigen vaccine, I.M injection
Description: Patients will receive a fixed applicable dose of ABOR2014(IPM511) administered.
Study: NCT05714904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZVS101e
Description: ZVS101e is developed by Chigenovo Co., Ltd., it contains recombinant adeno-associated virus serotype 8 (rAAV8) vectors which carry human CYP4V2 gene.
Study: NCT04783688

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Full Face Snorkel Mask (FFSM)
Description: A mask used for snorkeling that covers the entire face, as opposed to a conventional snorkel, which is held in the mouth only.
Study: NCT04722055

Intervention type: DIAGNOSTIC_TEST
Intervention: Multigene Methylation Detection Kit
Description: Eligible participants are required to take stool samples for multigene methylation detection and gene sequencing, undergo colonoscopy examination, and have a biopsy when necessary (gold standard).
Study: NCT06435559

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurotablet® and Neuropsychological evaluations
Description: The experimental group will carry out cognitive rehabilitation using the Neurotablet device. The cognitive rehabilitation will be performed for 10 consecutive weeks, once a week for 1 hour. Neuropsychological evaluations will be conducted before the start of chemotherapy (T0), 6 months (T1) and 12 months (T2) after the start of chemotherapy. Neuropsychological evaluations will include tests to analyze the main cognitive domains of memory, attention, executive functions and learning.

Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychological evaluations
Description: Neuropsychological evaluations will be conducted before the start of chemotherapy (T0), 6 months (T1) and 12 months (T2) after the start of chemotherapy. Neuropsychological evaluations will include tests to analyze the main cognitive domains of memory, attention, executive functions and learning.
Study: NCT06086015

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial alternating current stimulation (tACS)
Description: 2mA tACS over right hemisphere, at positions F4, P4, T8 (10-10 convention)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: transcranial alternating current stimulation (tACS)
Description: 2mA tACS over right hemisphere, at positions F4, P4, T8 (10-10 convention)
Study: NCT04598399

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Relapse Prevention
Description: 7 x 60-120 minute sessions with different themes: Automatic pilot/triggers/relapse/high-risk situations/ mindfulness in daily life. There will be a welcoming time, with a focus on at-home practice and difficulties, a theoretical presentation of new concepts, practical meditation exercises and a debriefing.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation/ meditation
Description: 7 x 60-120 minute sessions each with a different sound from nature with unguided, closed relaxation group with a maximum of 12 participants
Study: NCT04850781

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bi-weekly frozen meal home delivery
Description: All participants randomized to this arm will receive 10 frozen meals that are mailed to their home every two weeks from a MOW vendor, TRIO foods.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Daily home meal delivery
Description: All participants randomized to this arm will receive meals delivered to their home multiple times per week from a MOW program employee/volunteer with a wellness check and socialization.
Study: NCT06286176

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Videos with breastfeeding education material and encouraging messages
Description: Distributed videos aim to increase breastfeeding related knowledge and to receive support

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whatsapp group
Description: The Whatsapp group is used in the intervention as a platform for interpersonal exchange of information and experience, in addition to peer support.
Study: NCT05677672

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human TH-SC01 Cell Injection
Description: Single injection of 0.6×10\^7,1.2×10\^8, 1.8×10\^8 cells/kg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: saline solution will be given at the same quantity and following the same schedule
Study: NCT05945862

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NUTRIGANDO
Description: Program consisting in nutrition education and physical activity training to promote healthy lifestyles
Study: NCT05713669

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Encounter visit with Patients
Description: Participants in this encounter group will be asked to complete a pre and post-intervention survey, participate in a meeting with a former ICU patient at a post-ICU clinic, and undergo an in-person interview within fourteen days following the encounter.
Study: NCT05699148

Intervention type: DRUG
Intervention: Elexacaftor / Ivacaftor / Tezacaftor
Description: Triple combination therapy is licensed in the UK for prescription to paediatric patients aged 6 to 11 years. ETI will be started as part of routine clinical care.
Study: NCT06227832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP-001
Description: KP-001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP-001
Description: KP-001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP-001
Description: KP-001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: oral dose of 850 mg Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: oral dose of 2 mg Midazolam
Study: NCT04794140

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: different number of passes
Description: Each patient's operation process is the same, that is, after obtaining enough specimens for diagnosis by endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) wet suction technique, additional three passes are performed. One of which is randomly selected as the one pass group, and the other two passes automatically as the two pass group. Please refer to the literature for EUS-FNB wet technique (Tong T, et al. J Gastroenterol Hepatol. 2020;10.1111/jgh.15371.)
Study: NCT06227832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: oral doses of 1000 mg Clarithromycin
Study: NCT04125680

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ESL Health Literacy Classes
Description: The intervention will last 8-weeks, and the first and last classes will be devoted to survey assessments. Participants will be asked to reflect on their health knowledge and behaviors, and how they have changed since starting the program. The curriculum administered during the classes will use pedagogies for health literacy as a practice. It will focus on skills needed to learn about lead exposure in the ESL classroom: (1) vocabulary; (2) grammar; and (3) identifying risk factors, symptoms and preventive strategies. A focus on health literacy as practice will include personal engagement using language in context: (1) role-play interactions about lead exposure prevention; (2) discussing views about risk, and how to talk about it with peers and family members; (3) identifying sources of reliable health information; and (4) learning to ask for support and resources.
Study: NCT06005454

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil (Omega)
Description: We will use a dietary supplement source of omega 3 fatty acids from the available syrup ( each 5 ml contain 640 mg of high DHA Fish oil) so we will give it in a dose 2.7 ml twice daily for children between 1 and 3 years and 3.5 ml twice daily for children between 4 and 5 years.
Study: NCT05464017

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optimized version of the mHealth screening tool (intervention) using the machine learning approach
Description: An improvement to the mHealth triage tool using a machine learning approach, optimizing the efficiency of call schedule and the prediction of which patients are most likely to benefit from follow-up care given data collected at the hospital through the Cameroon Trauma Registry, as well as post-discharge phone contact attempts and survey information. The backbone of the estimators is the ensemble machine learning algorithm the Superlearner, which has been applied to medical contexts, including injury and trauma. It is a theory-driven method based on cross-validation, which combines potentially many different learners (e.g., standard regression, tree regression, random forest, neural nets) such that the model chosen (a weighted average of the learners) is asymptotically equivalent to the so called Oracle - the learner that fits optimally for the data-generating distribution. Note, double-robust CV-TMLE versions of this estimator are available as the tmle3mopttx function in tlverse.
Study: NCT04681092

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AKS-452
Description: s.c. or i.m. vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AKS-452
Description: s.c. or i.m. vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AKS-452
Description: s.c. or i.m. vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AKS-452
Description: s.c. or i.m. vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AKS-452
Description: s.c. or i.m. vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AKS-452
Description: s.c. or i.m. vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AKS-452
Description: s.c. or i.m. vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AKS-452
Description: s.c. or i.m. vaccination
Study: NCT05798988

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurophysiology-based exercise program
Description: Neurophysiology-based exercise program combines physiotherapy exercises and neuro-physiology principles with focus on foot and core functional stabilisation and balance training.
Study: NCT05713669

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Non-encounter surveys
Description: Surveys will be completed pre and post patient follow-up.
Study: NCT05301374

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Watching Cartoon
Description: Children in the cartoon group before the procedure, they chose one of the cartoons predetermined by the researchers. The children in the cartoon group started watching a cartoon of their choice 2 minutes before the procedure and they kept watching until the procedure was ended.
Study: NCT05688826

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sugar
Description: 75 g sugar dissolved in 0.8 dl water and flavored with lemon. Ingested during 5 minutes